BioSpace News Archive

NanoString Technologies, Inc. announced the publication of its first paper describing the CosMx™ Spatial Molecular Imager’s chemistry, reproducibility, and sensitivity, as well as the application of the technology to study non-small cell lung cancer and breast cancer samples in Nature Biotechnology.

DNA Script, a world leader in Enzymatic DNA Synthesis for DNA on demand, has signed distribution agreements in the Middle East with Gulf Scientific Corporation and Eisenberg Ltd. to expand its worldwide footprint of sales, service and support.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that three data presentations will occur at the CHEST 2022 Annual Meeting which will be held live and in-person for the first time since 2019.

Lung health research is more important than ever. Never have we faced so many challenges to our lung health, including COVID-19, vaping and smoke from increased wildfires.

Freudenberg Medical, a global developer and manufacturer of finished medical devices, components, and minimally invasive solutions for the medical device industry, has expanded industrial design and human factors engineering through the launch of a Handle Design Center of Excellence in Jeffersonville, Indiana.

Eagle Pharmaceuticals, Inc. announced today that it has submitted an investigational new drug application to the U.S. Food and Drug Administration for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the treatment of severe community-acquired bacterial pneumonia.

GreenLight Biosciences announced a realignment to focus on key near-term value drivers and extend its cash runway.

Leap Therapeutics, Inc. (Nasdaq:LPTX) today announced that the first patient has been enrolled in the randomized controlled Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap’s anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene’s anti-PD-1 antibody, and chemotherapy compared to a tislelizumab and chemotherapy control arm, in patients with gastric or gastroesophageal junction cancer (G/GEJ).

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA ® (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants.

ATP, a leader in life sciences venture capital, today announced the launch of Ascidian Therapeutics, a biotechnology company built and developed by ATP and funded with a $50 million Series A financing.